A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin

Trial Profile

A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Moxetumomab pasudotox (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 19 Nov 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Nov 2015 Planned End Date changed from 1 May 2017 to 1 Nov 2015 as reported by ClinicalTrials.gov.
    • 19 Nov 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top